Back

Pulmonary arterial hypertension involves pro-inflammatory monocytes and plasma mediators that promote endothelial dysfunction and inflammatory responses dependent on the severity: role of SGLT2

11 May 2026 (11:30 - 12:15)
Organised by: Logo
Congress Presentation Part of: Deciphering pathomechanisms in human heart failure and cardiomyopathy Drugs, Drug Targets HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Hira MUZAMMEL

Strasbourg (France)

4 More presentations in this session

Presentation thumbnail
Gliflozin therapy is associated with reduced monocyte activation and plasma-induced oxidative stress in endothelial cells and cardiomyocytes of patients with hypertrophic cardiomyopathy.
Doctor A. Mroueh (Strasbourg, FR)
Abstract Slides
Presentation thumbnail
Molecular pathology and clinical presentation of Slovenian patients with isolated cardiomyopathy and pathogenic variants in RASopathy-associated genes
Ms N. Vodnjov (Ljubljana, SI)
Abstract Slides
Presentation thumbnail
The profile of transthyretin amyloid cardiomyopathy in Germany and Spain: a real-world survey of cardiologists and patients
Doctor F. Dominguez (Madrid, ES)
Abstract Slides
Presentation thumbnail
Association of Lipoprotein(a) with coronary artery disease severity in acute myocardial infarction: evidence from a real-world cohort
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides

Access the full session

Session thumbnail
Deciphering pathomechanisms in human heart failure and cardiomyopathy

The Event

Event poster

Heart Failure 2026

11 May 2026 11:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources